A股异动|赛隆药业午后直线拉涨逾3%子公司获注射用帕瑞昔布钠药品注册批件
格隆汇8月13日丨赛隆药业(002898.SZ)午后直线拉升,现报13.48元,涨3.61%,暂成交442万元,最新总市值21.5亿元。赛隆药业午间发布公告称,全资子公司湖南赛隆药业于近日获得国家药监局核准签发的注射用帕瑞昔布钠《药品注册批件》,药品批准文号有效期至2024年8月1日。公告称,注射用帕瑞昔布钠具有镇痛效果好、起效迅速、作用持久、不影响血小板功能、不会额外增加心血管风险等特点,可广泛用于普通外科、妇科、骨科、口腔科等多个科室术后疼痛的治疗。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.